The use of molecular biomarker tests: an interview study with healthcare providers about a molecular biomarker test for prostate cancer.
Karine WendrichLotte KrabbenborgPublished in: Personalized medicine (2021)
Aim: Investigate why healthcare providers are not always willing to use molecular biomarker tests, even though they promise to personalize disease diagnosis and treatment. Materials & methods: We interviewed 20 Dutch urological healthcare providers to ascertain why they used or did not use SelectMDx, a biomarker test for prostate cancer. Results: Whether and how it was used differed from the developers' expectations, because users and nonusers disagreed about its perceived advantages; the scientific and clinical evidence; the advantages of MRI; and the value of PCA3 testing. Financial issues and the absence of SelectMDx in professional guidelines and hospital care pathways also hampered its use. Conclusion: Eliciting users' and nonusers' views is important to better understand how biomarker tests can be embedded in clinical practice.
Keyphrases
- healthcare
- prostate cancer
- clinical practice
- radical prostatectomy
- magnetic resonance imaging
- depressive symptoms
- mental health
- single molecule
- affordable care act
- palliative care
- machine learning
- social support
- computed tomography
- emergency department
- health information
- magnetic resonance
- pain management
- electronic health record
- social media
- artificial intelligence
- quality improvement
- chronic pain